
|Articles|February 1, 2006
February 2006 FDA Pipeline
New molecular entities
Advertisement
New molecular entities
Nexavar
Sorafenib tablets
Bayer/OnyxORAL THERAPY APPROVED FOR THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA
New indications
Avelox
Moxifloxacin
Bayer/Schering-PloughFLUOROQUINOLONE ANTIBIOTIC APPROVED FOR CIAI
Dosing. The recommended dose of moxifloxacin is 400 mg (orally or as an IV infusion) once every 24 hours. For cIAIs, therapy should usually be initiated with the IV formulation, and the duration of therapy should last from 5 to 14 days.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Congress challenges health insurers saying they put profits over patients
2
Physician groups said scope of practice will be the top state health policy issue in 2026, with Medicaid, workforce and telehealth also high priorities
3
AHIP lays blame for rising healthcare costs on hospitals, private equity
4
A conversation about dancing menopause away with Danielly Fausto, Ph.D., physical education researcher at the Santa Catarina State University in Brazil
5



















































